Editas Medicine, Inc. EDIT
At closeNov 4, 2026, 7:22 AM EST
Pre-market · Nov 4, 7:22 AM ET
- YTD
- +26.83%
- 1 year
- -6.47%
- Market cap
- 399.31M
- Revenue (ttm)
- 61.76M
- EPS (ttm)
- -0.70
- Shares out
- 82.55M
- Forward P/E
- -0.53
- YTD return
- +26.83%
- 1-year return
- -6.47%
- Volume
- 1.76M
- Avg volume
- 2.70M
- Open
- 2.61
- Previous close
- 2.57
- Day's range
- 2.57 – 2.71
- 52-week range
- 1.66 – 3.94
- Beta
- 2.01
- Analysts
- Hold
- Price target
- 3.67 (+41.0%)
5D 0.00 (0.00%)
Key statistics
- Enterprise value
- -118.46M
- PEG ratio
- 0.00
- Price / sales
- 1.67
- Price / book
- 0.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -98.90%
- Free cash flow
- -113.80M
- Total cash
- 265.09M
- Total debt
- 38.49M
- Return on equity
- -78.56%
- Short % of float
- 24.64%
- 50-day average
- 2.60
- 200-day average
- 4.55
Analyst view
Consensus: hold
- Target (low)
- 1.00
- Target (mean)
- 3.67
- Target (high)
- 8.00
- Strong buy0
- Buy4
- Hold12
- Sell0
- Strong sell2
Next earnings
Consensus EPS estimate -0.3561.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.76 | -0.75 | +0.01 | +1.32% |
| Aug 7, 2024 | Jun 1, 2024 | -0.69 | -0.82 | -0.13 | -18.84% |
| May 8, 2024 | Mar 1, 2024 | -0.63 | -0.76 | -0.13 | -20.63% |
| Feb 28, 2024 | Dec 1, 2023 | -0.52 | -0.23 | +0.29 | +55.77% |
| Nov 3, 2023 | Sep 1, 2023 | -0.64 | -0.55 | +0.09 | +14.06% |
| Aug 2, 2023 | Jun 1, 2023 | -0.76 | -0.56 | +0.20 | +26.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | Evercore ISI Group | main | Outperform | Outperform |
| Dec 16, 2024 | JP Morgan | down | Neutral | Underweight |
| Dec 13, 2024 | RBC Capital | main | Sector Perform | Sector Perform |
| Dec 13, 2024 | Barclays | main | Equal-Weight | Equal-Weight |
| Dec 13, 2024 | Chardan Capital | down | Buy | Neutral |
| Dec 13, 2024 | Baird | main | Outperform | Outperform |
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- editasmedicine.com
News
Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6 
Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia 
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday 
This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday 
Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target 
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket 
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday 
Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate 
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday 
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Your note
Sign in to keep a note on EDIT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURKLY LINDA | Officer | Sale | Jul 24, 2024 | 73,136 |
| EATON BRUCE E | Chairman of the Board | Sale | Dec 4, 2023 | 74,791 |
| HOPFIELD JESSICA | Director | Purchase | May 12, 2024 | 67,700 |
| LUCERA ERICK J. | Chief Financial Officer | Sale | May 19, 2024 | 116,829 |
| MEI BAISONG | Officer | Sale | Dec 2, 2024 | 133,354 |
| O NEILL GILMORE NEIL | Chief Executive Officer | Sale | Dec 2, 2024 | 312,106 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.72% | 8,024,709 | 10.03M | Sep 29, 2024 |
| Vanguard Group Inc | 8.09% | 6,679,606 | 8.35M | Sep 29, 2024 |
| Deep Track Capital, Lp | 5.94% | 4,900,334 | 6.13M | Sep 29, 2024 |
| Millennium Management Llc | 4.06% | 3,350,856 | 4.19M | Sep 29, 2024 |
| State Street Corporation | 2.98% | 2,462,022 | 3.08M | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 2.75% | 2,267,110 | 2.83M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.14% | 2,591,876 | 3.24M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.61% | 2,152,572 | 2.69M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.65% | 1,359,023 | 1.70M | Sep 29, 2024 |
| Vanguard Strategic Equity Fund | 1.44% | 1,189,890 | 1.49M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.03% | 850,449 | 1.06M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.95% | 784,487 | 980.61K | Oct 30, 2024 |